

## CONTENTS

### Advances in Brief

- 1639 Wild-Type p53 Demonstrates Functional Dominance in a Human Colon Carcinoma Cell Line in Which It Induces Reversible Growth Arrest.** Bin Yang, Peter J. Stambrook, and Sanford D. Markowitz.
- 1649 Wild-Type p53 Protein Potentiates Cytotoxicity of Therapeutic Agents in Human Colon Cancer Cells.** Bin Yang, James R. Eshleman, Nathan A. Berger, and Sanford D. Markowitz.

### Research Articles

- 1659 Evaluation of Topical Gene Therapy for Head and Neck Squamous Cell Carcinoma in an Organotypic Model.** Susan A. Eicher, Gary L. Clayman, Ta-Jen Liu, Edward J. Shillitoe, Karen A. Storthz, Jack A. Roth, and Reuben Lotan.
- 1665 Adenoviral-mediated Wild-Type p53 Gene Expression Sensitizes Colorectal Cancer Cells to Ionizing Radiation.** Francis R. Spitz, Dao Nguyen, John M. Skibber, Raymond E. Meyn, Richard J. Cristiano, and Jack A. Roth.
- 1673 13q14 Deletions Are Not Primary Events in B-Cell Chronic Lymphocytic Leukemia: A Study of 100 Patients Using Fluorescence *in Situ* Hybridization.** Hervé Avet-Loiseau, Marie-Claire Devilder, Richard Garand, Isabelle Bouyge, Marie-José Rapp, Noël Milpied, Jean-Luc Harousseau, Jean-Paul Moisan, and Régis Bataille.
- 1679 Significance of Vessel Count and Vascular Endothelial Growth Factor and Its Receptor (*KDR*) in Intestinal-type Gastric Cancer.** Yutaka Takahashi, Karen R. Cleary, Masayoshi Mai, Yasuhiko Kitadai, Corazon D. Bucana, and Lee M. Ellis.
- 1685 Phase I Trial of the Thymidylate Synthase Inhibitor AG331 as a 5-Day Continuous Infusion.** Peter J. O'Dwyer, Paul B. Laub, Deborah DeMaria, Mingxin Qian, Denise Reilly, Bruce Giantonio, Amanda L. Johnston, Ellen Y. Wu, Lisa Bauman, Neil J. Clendeninn, and James M. Gallo.
- 1693 Modulation of Platinum Sensitivity and Resistance by Cyclosporin A in Refractory Ovarian and Fallopian Tube Cancer Patients: A Phase II Study.** Setsuko K. Chambers, Carol A. Davis, Peter E. Schwartz, Ernest I. Kohorn, and Joseph T. Chambers.
- 1699 Phase I Trial of Intravenous Carboplatin and Cyclosporin A in Refractory Gynecologic Cancer Patients.** Setsuko K. Chambers, Carol A. Davis, Joseph T. Chambers, Peter E. Schwartz, Marc I. Lorber, and Robert E. Handschumacher.
- 1705 Decreases in Levels of Serum Fibronectin Predict the Severity of Vascular Leak Syndrome in Patients Treated with Ricin A Chain-containing Immunotoxins.** Roxana Baluna, Edward A. Sausville, Marvin J. Stone, Mary Alice Stetler-Stevenson, Jonathan W. Uhr, and Ellen S. Vitetta.
- 1713 Effects of PIXY321, a Granulocyte-Macrophage Colony-stimulating Factor/Interleukin 3 Fusion Protein, on Human Tumor Colony-forming Units Taken Directly from Patients.** Miguel A. Izquierdo, Donna Degen, Eric Raymond, Dania Caron, Veronica Ortiz, Peter Banks, and Daniel D. Von Hoff.
- 1717 Phase I Clinical and Pharmacokinetic Study of Carzelesin (U-80244) Given Daily for Five Consecutive Days.** Inge Wolff, Karin Bench, Jos H. Beijnen, Uta Brunsch, Franco Cavalli, Jolanda de Jong, Yvonne Groot, Olaf van Tellingen, Jantien Wanders, and Cristiana Sessa for the Early Clinical Studies Group of the EORTC.
- 1725 Paclitaxel (Taxol<sup>®</sup>) Inhibits Motility of Paclitaxel-resistant Human Ovarian Carcinoma Cells.** Dorina Belotti, Monica Rieppi, Maria Ines Nicoletti, Anna Maria Casazza, Tito Fojo, Giulia Taraboletti, and Raffaella Giavazzi.
- 1731 Fludarabine-mediated Inhibition of Nucleotide Excision Repair Induces Apoptosis in Quiescent Human Lymphocytes.** Alex Sandoval, Ugo Consoli, and William Plunkett.
- 1743 Interleukin 13 Inhibits Growth of Human Renal Cell Carcinoma Cells Independently of the p140 Interleukin 4 Receptor Chain.** Nicholas I. Obiri, S. Rafat Husain, Waldemar Debinski, and Raj K. Puri.
- 1751 Effect of Omega-3 Fatty Acids on the Progression of Metastases after the Surgical Excision of Human Breast Cancer Cell Solid Tumors Growing in Nude Mice.** David P. Rose, Jeanne M. Connolly, and Melissa Coleman.
- 1757 Quantitation of Somatostatin Receptor Type 2 Gene Expression in Neuroblastoma Cell Lines and Primary Tumors Using Competitive Reverse Transcription-Polymerase Chain Reaction.** R. Sestini, C. Orlando, A. Peri, C. Tricarico, M. Pazzagli, M. Serio, A. Pagani, G. Bussolati, S. Granchi, and M. Maggi.

- 1767 Anti-p53 Antibodies in Sera from Patients with Chronic Obstructive Pulmonary Disease Can Predate a Diagnosis of Cancer.** Glenwood E. Trivers, Virna M. G. De Benedetti, Helen L. Cawley, Gail Caron, Anita M. Harrington, William P. Bennett, James R. Jett, Thomas V. Colby, Henry Tazelaar, Peter Pairolero, Roland D. Miller, and Curtis C. Harris.
- 1777 Expression of the  $M_r$  67,000 Laminin Receptor Is an Adverse Prognostic Indicator in Human Thyroid Cancer: An Immunohistochemical Study.** Fulvio Basolo, Luca Pollina, Furio Pacini, Gabriella Fontanini, Sylvie Ménard, Vincent Castronovo, and Generoso Bevilacqua.
- 1781 Determination of the Prognostic Significance of Un-scheduled Cyclin A Overexpression in Patients with Esophageal Squamous Cell Carcinoma.** Mutsuo Furihata, Tadanori Ishikawa, Atsushi Inoue, Chiaki Yoshikawa, Hiroshi Sonobe, Yuji Ohtsuki, Keijiro Araki, and Shohei Ogoshi.
- 1787 Increased Epidermal Growth Factor Receptor Expression in Metaplastic Bronchial Epithelium.** Jonathan M. Kurie, Hyung Ju C. Shin, Jin Soo Lee, Rudolfo C. Morice, Jae Y. Ro, Scott M. Lippman, Walter N. Hittelman, Ren Yu, J. Jack Lee, and Waun Ki Hong.
- 1795 Molecular Screening of Multifocal Transitional Cell Carcinoma of the Bladder Using p53 Mutations as Biomarkers.** Xiaohui Xu, Mike J. Stower, I. Nick Reid, R. Colin Garner, and Philip A. Burns.
- 1801 Prediction of Occult Neck Metastases in Laryngeal Carcinoma: Role of Proliferating Cell Nuclear Antigen, MIB-1, and E-Cadherin Immunohistochemical Determination.** Alessandro Franchi, Oreste Gallo, Vieri Boddi, and Marco Santucci.
- 
- 1809 AACR Bulletin Board**  
Institution of Page Charges  
Annual Meeting  
Call for Nominations for Honorary Membership  
Gertrude Elion Cancer Research Award  
AACR Research Fellowships  
AACR Minority Scholar Awards Supported by the National Cancer Institute  
AACR Special Conferences in Cancer Research
- i Instructions for Authors**

# Clinical Cancer Research

**2 (10)**

*Clin Cancer Res* 1996;2:1639-1808.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/2/10.citation>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/2/10.citation>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.